Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with CKD

Visit Radcliffe Cardiology: www.radcliffec...
Dr Kate Wilcox, CardioNerds Academic Fellow (Medical College of Wisconsin, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr David L Preiss (University of Oxford, Oxford, UK), investigator of the late-breaking EMPA-Kidney trial.
The trial, first presented AHA 22, looked at the SGLT2i, empagliflozin's effect on kidney disease progression or cardiovascular death compared to placebo on top of standard of care in 6609 patients with pre-existing chronic kidney disease (CKD). EMPA-Kidney demonstrated that the treatment with empagliflozin reduced kidney disease progression or CV death.
For the longer version of this discussion with more information on methodology click here.
Recorded remotely from Oxford and Milwaukee, 2022.
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

[@ameliacarro]

This was a very interesting review for anyone interested in the topic. Congratulations and thank you

[@ahmedahm1]

7:20